The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.
 
Wenfeng Fang
No Relationships to Disclose
 
Qiming Wang
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Yongzhong Luo
No Relationships to Disclose
 
Xiujuan Qu
No Relationships to Disclose
 
Haibo Zhu
No Relationships to Disclose
 
Zhenyu Ding
No Relationships to Disclose
 
XingYa Li
No Relationships to Disclose
 
Lin Wu
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Hengrui Medicine; Innovate Biopharmaceuticals; Lilly; MSD; Pfizer; Roche China
 
Yan Wang
No Relationships to Disclose
 
Sheng Hu
No Relationships to Disclose
 
Enwen Wang
No Relationships to Disclose
 
Anwen Liu
No Relationships to Disclose
 
Yuping Sun
Honoraria - AstraZeneca; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Roche
Research Funding - Pfizer; Roche
 
Yun Fan
No Relationships to Disclose
 
Feng Ye
No Relationships to Disclose
 
Kaihua Lu
No Relationships to Disclose
 
Yalan Yang
No Relationships to Disclose
 
Junyou Ge
No Relationships to Disclose
 
Li Zhang
No Relationships to Disclose